IFNB1 and hepatitis C virus infection: In hepatitis C, the anti-viral action of IFN-β has been shown to be dose-dependent and more pronounced over 48 h, which reinforces the concept of the need for more aggressive dosing at treatment initiation (Hosseini-Moghaddam et al., 2009).